KRAS and non-small cell lung carcinoma: In addition, an shRNA library screen against human kinases recently identified FGFR1 as a strong sensitizing hit using trametinib, and FGFR inhibitors combined with trametinib were effective in KRAS mutant NSCLC xenografts as well as genetically engineered mouse models [15].